World's Best Scientists 2026 revealed!

D-Index & Metrics

Neuroscience

D-Index
65
Citations
12853
World Ranking
3162
National Ranking
182

Best Publications

  • Detection of Huntington’s disease decades before diagnosis: The Predict HD study

    Jane Paulsen;Douglas R Langbehn;Julie C Stout;Elizabeth H Aylward

  • Levodopa in the treatment of Parkinson's disease: current controversies.

    C. Warren Olanow;Yves Agid;Yoshi Mizuno;Alberto Albanese

  • Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease

    Stephen J. Kish;Junchao Tong;Oleh Hornykiewicz;Ali Rajput

  • Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)

    Peter A. LeWitt;Peter A. LeWitt;M. Guttman;James W. Tetrud;Paul J. Tuite

  • The role of radiotracer imaging in Parkinson disease

    B. Ravina;D. Eidelberg;J. E. Ahlskog;R. L. Albin

  • Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease

    Mark Guttman

  • Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment.

    Mark Stacy;Annette Bowron;Mark Guttman;Robert Hauser

  • Clinical markers of early disease in persons near onset of Huntington’s disease

    J. S. Paulsen;H. Zhao;J. C. Stout;R. R. Brinkman

  • Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease

    J. M. Wilson;A. I. Levey;A. Rajput;L. Ang

  • [11C]RTI‐32 PET studies of the dopamine transporter in early dopa‐naive Parkinson's disease Implications for the symptomatic threshold

    M. Guttman;J. Burkholder;S. J. Kish;D. Hussey

  • Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease

    Shannon A Johnson;Shannon A Johnson;Julie C Stout;Julie C Stout;Andrea C Solomon;Douglas R Langbehn

  • Thalamic metabolism and symptom onset in preclinical Huntington's disease.

    A. Feigin;C. Tang;Y. Ma;P. Mattis

  • Brain serotonin transporter binding in non‐depressed patients with Parkinson's disease

    M. Guttman;I. Boileau;J. Warsh;J. A. Saint-Cyr

  • Current concepts in the diagnosis and management of Parkinson's disease

    Mark Guttman;Stephen J. Kish;Yoshiaki Furukawa

  • Brain α-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation

    Junchao Tong;Henry Wong;Mark Guttman;Lee C. Ang

  • Dopa decarboxylase activity of the living human brain.

    Albert Gjedde;Jakob Reith;Suzan Dyve;Gabriel Leger

  • Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[11C]DASB and structural brain imaging study

    Stephen J. Kish;Jason Lerch;Yoshiaki Furukawa;Junchao Tong

  • Influence of l-dopa and pramipexole on striatal dopamine transporter in early PD

    M. Guttman;D. Stewart;D. Hussey;A. Wilson

  • Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.

    Junchao Tong;Gausiha Rathitharan;Jeffrey H Meyer;Yoshiaki Furukawa

  • Burden of parkinsonism: a population-based study.

    Mark Guttman;Pamela M. Slaughter;Marc‐Erick Theriault;Donald P. DeBoer

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: